Compare ASTRAZENECA PHARMA with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs GSK PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA GSK PHARMA ASTRAZENECA PHARMA/
GSK PHARMA
 
P/E (TTM) x 89.3 248.1 36.0% View Chart
P/BV x 27.1 11.0 245.3% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 ASTRAZENECA PHARMA   GSK PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
GSK PHARMA
Mar-19
ASTRAZENECA PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2783,595 35.5%   
Low Rs8831,253 70.4%   
Sales per share (Unadj.) Rs228.4184.7 123.7%  
Earnings per share (Unadj.) Rs10.426.3 39.4%  
Cash flow per share (Unadj.) Rs16.329.2 55.8%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs98.8126.3 78.2%  
Shares outstanding (eoy) m25.00169.40 14.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.713.1 36.0%   
Avg P/E ratio x104.292.2 113.1%  
P/CF ratio (eoy) x66.483.1 79.9%  
Price / Book Value ratio x10.919.2 57.0%  
Dividend payout %076.1 0.0%   
Avg Mkt Cap Rs m27,008410,626 6.6%   
No. of employees `0001.45.0 27.3%   
Total wages/salary Rs m1,5355,372 28.6%   
Avg. sales/employee Rs Th4,210.96,306.7 66.8%   
Avg. wages/employee Rs Th1,132.21,083.1 104.5%   
Avg. net profit/employee Rs Th191.1898.0 21.3%   
INCOME DATA
Net Sales Rs m5,71031,281 18.3%  
Other income Rs m1231,023 12.0%   
Total revenues Rs m5,83332,304 18.1%   
Gross profit Rs m4636,009 7.7%  
Depreciation Rs m147486 30.3%   
Interest Rs m06 0.0%   
Profit before tax Rs m4386,540 6.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m1792,373 7.5%   
Profit after tax Rs m2594,454 5.8%  
Gross profit margin %8.119.2 42.2%  
Effective tax rate %40.836.3 112.6%   
Net profit margin %4.514.2 31.9%  
BALANCE SHEET DATA
Current assets Rs m3,20920,061 16.0%   
Current liabilities Rs m2,07014,543 14.2%   
Net working cap to sales %20.017.6 113.1%  
Current ratio x1.61.4 112.4%  
Inventory Days Days7257 127.4%  
Debtors Days Days3514 248.4%  
Net fixed assets Rs m79014,343 5.5%   
Share capital Rs m501,694 3.0%   
"Free" reserves Rs m2,41919,704 12.3%   
Net worth Rs m2,46921,398 11.5%   
Long term debt Rs m02 0.0%   
Total assets Rs m4,60539,113 11.8%  
Interest coverage xNM1,091.0-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.8 155.0%   
Return on assets %5.611.4 49.3%  
Return on equity %10.520.8 50.4%  
Return on capital %17.731.9 55.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m300534 56.1%   
Fx outflow Rs m2,0157,091 28.4%   
Net fx Rs m-1,715-6,557 26.2%   
CASH FLOW
From Operations Rs m883,994 2.2%  
From Investments Rs m-94-1,433 6.5%  
From Financial Activity Rs mNA-3,584 0.0%  
Net Cashflow Rs m-6-1,023 0.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 50.7 147.9%  
Indian inst/Mut Fund % 0.3 10.2 2.9%  
FIIs % 15.7 23.8 66.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 15.4 59.1%  
Shareholders   12,856 102,036 12.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   DIVIS LABORATORIES  WOCKHARDT  VENUS REMEDIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 1,266 Points; Nifty Ends Above 9,100 Mark(Closing)

Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

SUN PHARMA Surges by 6%; BSE HEALTHCARE Index Up 4.7% (Market Updates)

Apr 9, 2020 | Updated on Apr 9, 2020

SUN PHARMA share price has surged by 6% and its current market price is Rs 470. The BSE HEALTHCARE is up by 4.7%. The top gainers in the BSE HEALTHCARE Index are SUN PHARMA (up 6.3%) and ASTRAZENECA PHARMA (up 5.2%). The top losers are IPCA LABS (down 0.8%) and TORRENT PHARMA (down 0.9%).

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

A Safe Stock to Lockdown Now(The 5 Minute Wrapup)

Apr 2, 2020

The market crashc has made strong, established brands attractive. Here's a stock to make the most of this opportunity...

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak(Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

How to Identify a Market Rebound(Fast Profits Daily)

Mar 27, 2020

This very useful indicator can spot a market bottom.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Apr 9, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS